AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

NASDAQ:AMRSAmyris Stock Price, Forecast & News

$4.86
-0.49 (-9.16 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.66
Now: $4.86
$5.27
50-Day Range
$2.25
MA: $2.98
$5.35
52-Week Range
$1.40
Now: $4.86
$6.07
Volume7.00 million shs
Average Volume2.36 million shs
Market Capitalization$796.52 million
P/E RatioN/A
Dividend YieldN/A
Beta0.49
Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Read More
Amyris logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
Current SymbolNASDAQ:AMRS
CUSIP03236M10
Phone510-450-0761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$152.56 million
Book Value($2.17) per share

Profitability

Net Income$-242,770,000.00
Net Margins-154.49%

Miscellaneous

Employees414
Market Cap$796.52 million
Next Earnings Date10/5/2020 (Estimated)
OptionableOptionable

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

Amyris (NASDAQ:AMRS) Frequently Asked Questions

How has Amyris' stock been impacted by COVID-19 (Coronavirus)?

Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMRS shares have increased by 64.2% and is now trading at $4.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amyris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amyris.

When is Amyris' next earnings date?

Amyris is scheduled to release its next quarterly earnings announcement on Monday, October 5th 2020. View our earnings forecast for Amyris.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) announced its quarterly earnings results on Friday, May, 8th. The biotechnology company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.37. The biotechnology company had revenue of $29.13 million for the quarter, compared to the consensus estimate of $34.51 million. View Amyris' earnings history.

When did Amyris' stock split? How did Amyris' stock split work?

Amyris's stock reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

What guidance has Amyris issued on next quarter's earnings?

Amyris issued an update on its FY 2020 Pre-Market earnings guidance on Friday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $220.32-220.32 million, compared to the consensus revenue estimate of $246.44 million.

What price target have analysts set for AMRS?

2 Wall Street analysts have issued 1 year price objectives for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Amyris' stock price to reach $9.50 in the next year. This suggests a possible upside of 95.5% from the stock's current price. View analysts' price targets for Amyris.

Has Amyris been receiving favorable news coverage?

Media stories about AMRS stock have trended very negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amyris earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAmyris.

Who are some of Amyris' key competitors?

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Advanced Micro Devices (AMD), Canopy Growth (CGC), Intel (INTC), Inovio Pharmaceuticals (INO), Novavax (NVAX), AT&T (T), Bank of America (BAC) and Corbus Pharmaceuticals (CRBP).

Who are Amyris' key executives?

Amyris' management team includes the following people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 53)
  • Ms. Kathleen Valiasek, Chief Financial Officer (Age 55)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 55)
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 52)
  • Dr. Joel R. Cherry, Pres of R&D (Age 58)

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Who are Amyris' major shareholders?

Amyris' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (3.96%), BlackRock Inc. (2.83%), Pinnacle Associates Ltd. (1.15%), State Street Corp (0.68%), Geode Capital Management LLC (0.46%) and Nuveen Asset Management LLC (0.18%). Company insiders that own Amyris stock include Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View institutional ownership trends for Amyris.

Which institutional investors are selling Amyris stock?

AMRS stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, BlackRock Inc., Jane Street Group LLC, JPMorgan Chase & Co., Levin Capital Strategies L.P., Morgan Stanley, UBS Group AG, and Virtus ETF Advisers LLC. Company insiders that have sold Amyris company stock in the last year include John Melo, and Patrick Y Yang. View insider buying and selling activity for Amyris.

Which institutional investors are buying Amyris stock?

AMRS stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Pinnacle Associates Ltd., KPCB XII Associates LLC, State Street Corp, Alliancebernstein L.P., Nuveen Asset Management LLC, Geode Capital Management LLC, and Paloma Partners Management Co. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, L John Doerr, and Patrick Y Yang. View insider buying and selling activity for Amyris.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $4.86.

How big of a company is Amyris?

Amyris has a market capitalization of $796.52 million and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 414 workers across the globe.

What is Amyris' official website?

The official website for Amyris is amyris.com.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.